Qiagen Stock Price, News & Analysis

QIAGEN N.V. (QGEN) is a Netherlands-based holding company that describes itself as a global leader in Sample to Insight solutions. The company focuses on enabling customers to extract and analyze molecular information from biological samples that contain the building blocks of life. QIAGEN’s activities are closely aligned with the biological product manufacturing and molecular diagnostics space, and its shares have been listed on the New York Stock Exchange under the symbol QGEN and on the Frankfurt Prime Standard under the symbol QIA.

According to QIAGEN, its Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies then prepare these biomolecules for analysis, while bioinformatics offerings support the interpretation of complex data to deliver insights. Automation solutions integrate these steps into streamlined workflows that are designed to be cost-effective for laboratories. The company reports that it serves more than 500,000 customers worldwide across Life Sciences and Molecular Diagnostics, including academia, pharmaceutical R&D, industrial applications such as forensics, and clinical healthcare.

Business focus and growth pillars

QIAGEN has outlined five growth pillars that frame its business focus across life sciences and diagnostics customers:

• Sample technologies – core solutions for isolating and processing nucleic acids and proteins from a wide range of biological materials.
• QIAstat-Dx syndromic testing – a PCR-based platform for syndromic testing, with panels for respiratory, gastrointestinal and central nervous system infections, and higher-throughput options such as QIAstat-Dx Rise.
• QIAcuity digital PCR – a digital PCR platform used in pharmaceutical, biopharma, academic and clinical research applications.
• QIAGEN Digital Insights (QDI) – bioinformatics and AI-enabled software solutions that help interpret genomics and clinical data, including platforms such as Franklin.
• QuantiFERON – blood-based tests for latent tuberculosis infection, with ongoing development of new generations and related chemistries.

These pillars reflect areas where QIAGEN reports that it is scaling differentiated platforms, including sample preparation, syndromic testing, digital PCR, bioinformatics and latent tuberculosis testing. The company has also highlighted targeted acquisitions, such as Parse Biosciences and Genoox (Franklin platform), as ways to expand its sample technologies and bioinformatics portfolios, particularly in single-cell analysis and AI-driven biology.

Sample technologies and automation

Sample technologies are central to QIAGEN’s identity. The company states that its technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. These capabilities underpin a range of instruments and kits used in laboratories worldwide.

QIAGEN emphasizes automation as a way to move customers from manual to automated workflows. Examples mentioned in company communications include:

• QIAcube family – automated instruments that replicate QIAGEN spin-column kits in a hands-off format. QIAGEN has reported thousands of QIAcube Connect placements and nearly 13,000 cumulative placements of QIAcube platforms since launch.
• QIAsymphony Connect – the next generation of an automated nucleic acid purification platform, designed for higher throughput, enhanced connectivity and support for applications such as liquid biopsy and oncology workflows.
• QIAsprint and QIAmini – additional automation systems aimed at high-throughput and lower-throughput labs respectively, extending automation across different laboratory scales.
• EZ2 Connect Fx – a system used with the EZ2 DNA Investigator Sep&Prep Kit to automate sexual assault sample processing for forensic laboratories.

These systems are described as part of a broader automation portfolio that addresses laboratory needs from individual users to large clinical testing facilities, and that can be integrated with QIAGEN’s digital ecosystem, such as the QIAsphere platform for remote monitoring and workflow optimization.

Molecular diagnostics and syndromic testing

In molecular diagnostics, QIAGEN highlights the QIAstat-Dx family of syndromic testing systems and panels. These systems use real-time PCR-based detection of multiple pathogens from a single sample and are intended to support rapid diagnosis of infectious diseases.

Key elements described by the company include:

• QIAstat-Dx Analyzer and QIAstat-Dx Rise – platforms that can run multiple panels, with QIAstat-Dx Rise designed for higher throughput and the ability to process up to 160 tests per day across multiple analytical modules.
• Panels for respiratory, gastrointestinal and CNS infections – including CE-IVDR certified panels in Europe and FDA-cleared respiratory panels in the U.S.
• Meningitis/Encephalitis (ME) Panel – an expanded CE-IVDR panel with 16 clinically relevant targets for CNS infections, including cytomegalovirus and Streptococcus pyogenes.

QIAGEN notes that QIAstat-Dx panels are designed to provide fast and comprehensive results in about an hour, with minimal hands-on time, and to offer features such as cycle threshold values and amplification curves directly on the instrument touchscreen.

Digital PCR and bioinformatics

Through the QIAcuity digital PCR platform, QIAGEN addresses applications in academia, biopharma and clinical research. The company has described plans to expand the QIAcuity portfolio with additional gene expression assays and workflow automation, including an automated nanoplate handling solution co-developed with Hamilton on the Microlab STAR platform.

QIAGEN Digital Insights (QDI) represents the company’s bioinformatics and software arm. QIAGEN reports that QDI provides AI-enabled software solutions for pharmaceutical R&D, clinical reporting and decision support in areas such as oncology and hereditary disease diagnostics. The integration of the Franklin platform, acquired with Genoox, is cited as an example of combining curated clinical interpretation content with AI-supported workflows for genetic analysis and reporting.

QuantiFERON and infectious disease testing

QIAGEN’s QuantiFERON products focus on latent tuberculosis testing. The company has described ongoing development of a fifth generation of its QuantiFERON test and investments in workflow automation and AI-related tools to support laboratories and clinical decision-making.

QIAGEN also collaborates with partners, such as Diasorin, on assays like the LIAISON QuantiFERON-TB Gold Plus II, which is designed for automated platforms and higher testing throughput. The company notes that a significant portion of the global latent TB testing market still relies on traditional skin tests, highlighting the role of blood-based diagnostics like QuantiFERON.

Life sciences, forensics and precision oncology

In Life Sciences, QIAGEN states that it serves academic researchers, pharmaceutical R&D and industrial applications such as forensics. For example, the EZ2 DNA Investigator Sep&Prep Kit is presented as a fully automated solution for processing sexual assault samples on the EZ2 Connect Fx instrument, aiming to improve sperm DNA recovery and reduce manual variability in forensic workflows.

QIAGEN also highlights activity in precision oncology, including Sample to Insight workflows for comprehensive genomic profiling based on Element Biosciences Trinity technology and collaborations with partners such as Myriad Genetics on homologous recombination deficiency assays. These efforts combine sample preparation, sequencing workflows and bioinformatics tools such as CLC Genomics Workbench and QCI Interpret.

Single-cell analysis and acquisitions

Single-cell analysis is a stated growth area for QIAGEN. The company has announced an agreement to acquire Parse Biosciences, a provider of scalable, instrument-free single-cell solutions based on its Evercode chemistry. QIAGEN describes this acquisition as expanding its Sample technologies portfolio into the single-cell sequencing market and supporting AI-driven biology through large-scale cellular datasets.

Parse’s technologies, including Evercode and the GigaLab service, are presented as enabling analysis of millions and billions of cells and supporting multi-million cell projects in areas such as oncology, immunology and neurology. QIAGEN has also indicated plans to integrate single-cell datasets generated through Parse into QDI to develop predictive modeling and target discovery tools.

Global footprint and customer base

QIAGEN reports that it serves more than 500,000 customers worldwide in Life Sciences and Molecular Diagnostics. The company notes that it has more than 35 locations and thousands of employees globally. Its customer base spans academic institutions, pharmaceutical and biotechnology companies, industrial laboratories (including forensics) and clinical healthcare providers.

Capital markets and listing status

QIAGEN N.V. has been listed on the New York Stock Exchange under the ticker QGEN and on the Frankfurt Stock Exchange (Prime Standard) under the ticker QIA. A Form 25 filed by the New York Stock Exchange in January 2026 indicates a notification of removal from listing and/or registration of QIAGEN N.V. common shares under Section 12(b) of the Securities Exchange Act of 1934. This filing confirms that the NYSE has taken steps to strike the class of securities from listing and/or withdraw registration on that exchange. The filing does not, by itself, describe any change to the company’s underlying operations.

Investor communications and reporting

As a foreign private issuer, QIAGEN furnishes reports on Form 6-K and prepares quarterly reports under U.S. GAAP that are incorporated by reference into these filings. The company regularly discusses the use of adjusted (non-GAAP) financial measures and constant currency metrics to supplement its GAAP-reported results. These communications provide context on revenue composition, profitability, capital allocation and other financial topics, but the core of QIAGEN’s business remains its Sample to Insight solutions across life sciences and molecular diagnostics.

How QIAGEN fits within biological product manufacturing

Within the broader category of biological product manufacturing, QGEN represents a company focused on enabling molecular analysis rather than on therapeutic products. Its technologies and platforms are intended to help laboratories and clinicians move from biological samples to interpretable molecular information, supporting research, diagnostics, forensics and other applications that rely on DNA, RNA and protein analysis.